Bioresorbable Scaffolds Market size is expected to be propelled over 2023 to 2032, driven by the alarming prevalence of cardiovascular diseases worldwide. As per the WHO estimates, CVDs claim more than 17.5 million lives each year. Bioresorbable scaffolds play a pivotal role in cardiovascular surgeries. Benefits offered by bioresorbable scaffolds such as it completely gets absorbed by the body leaving no foreign material will augment its demand in coming years.
Rising strategic initiatives undertaken by industry players to develop bioresorbable scaffolds will increase its adoption in the coming years. Companies are emphasizing on R&D projects and collaborations to develop scaffolds that can be completely absorbed and naturally restore movement of artery. For instance, in 2023, Evonik announced collaboration with BellaSeno to commercialize 3D-printed scaffolds for bone regeneration. The scaffolds are developed with Evonik’s Resomer polymers are used for complex and large bone defects.
Credible to note that the bioresorbable scaffolds market is likely to face growth challenges in the Ukrainian economy, given the ongoing Russia-Ukraine war impact. Sudden halt in cardiovascular and other procedures in the country has impacted the sales of bioresorbable scaffolds.
Drug eluting coronary scaffolds segment is slated to amass considerable gains through 2023. Drug eluting coronary scaffolds are majorly used in setting of primary angioplasty and boast of benefits such as reduced risk of infections and biodegradable property that enhances surgical outcomes. Additionally, drug eluting coronary scaffolds limit incidences of stent thrombosis and restenosis to restore vascular physiology. These characteristics enhance patient outcome, fueling the segment revenue.
Bioresorbable scaffolds market size from absorbable magnesium stent (AMS) segment is anticipated to witness robust demand over the forecast timeframe. AMS has ability to efficiently treat previously stented site to allow bypass graft without interrupting the existing implant. They also successfully deliver anti-restenosis drugs.
Based on end-user, the hospital segment is anticipated to record appreciable returns over the analysis timeline. The expansioncan be attributed to the growing chronic disease burden globally. Scaffolds have pivotal role in cardiovascular surgeries to unclog the obstructed blood flow in arteries and veins. Furthermore, initiatives taken by public hospitals to offer quality and cost-effective treatment make it easier for patients to afford bioresorbable scaffolds.
Regionally, North America is estimated to emerge as a profitable avenue for bioresorbable scaffolds market over the next 10 years. Lucrative opportunities in the market can be ascribed to demographic trends of the region such as growing baby boomers susceptible to numerous chronic conditions, rising disease burden and changing lifestyle of people. Additionally, strong foothold of industry players in the region will provide innovative solutions that will increase adoption rate and prove beneficial for the market value.
Notable industry players operating in the bioresorbable scaffolds market are Abbott, Medtronic, Boston Scientific Corporation, Biotronik, Elixir Medical Corporation, REVA Medical, Amaranth Medical, Kyoto Medical Planning, Xenogenics Corporation, B. Braun, Cardinal Health, Lombard Medical, Translumina, MicroPort Scientific Corporation and TERUMO CORPORATION.